Bioqual, Inc. (BIOQ)

Market Cap	49.19M
Revenue (ttm)	49.00M
Net Income (ttm)	-2.13M
Shares Out	894.42K
EPS (ttm)	-2.38
PE Ratio	n/a
Forward PE	n/a
Dividend	0.50 (0.91%)
Ex-Dividend Date	Oct 7, 2024

Volume	200
Average Volume	355
Open	60.00
Previous Close	57.50
Day's Range	55.00 - 60.00
52-Week Range	55.00 - 75.00
Beta	0.07
RSI	27.28
Earnings Date	Apr 21, 2025

About Bioqual

Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow c...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1981
• Employees: 113
• Stock Exchange: OTCMKTS
• Ticker Symbol: BIOQ

Financial Performance

In 2024, Bioqual's revenue was $58.59 million, a decrease of -6.50% compared to the previous year's $62.66 million. Earnings were $483,481, a decrease of -42.14%.